SU1163862A1 - Method of testing thyrotoxicosis cases - Google Patents
Method of testing thyrotoxicosis cases Download PDFInfo
- Publication number
- SU1163862A1 SU1163862A1 SU813282263A SU3282263A SU1163862A1 SU 1163862 A1 SU1163862 A1 SU 1163862A1 SU 813282263 A SU813282263 A SU 813282263A SU 3282263 A SU3282263 A SU 3282263A SU 1163862 A1 SU1163862 A1 SU 1163862A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- thyrotoxicosis
- content
- increase
- treatment
- testing
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
СПОСОБ :ЛЕЧЕНИЯ БОЛЬНЫХ ТИРЕОТОКСИКОЗОМ путем медикаментозного лечени антитиреоиднь1ми средствами, о тличающийс тем, что, с целью снижени осложнений, в крови определ ют содержание кортизола до и после введени АКТГ и при увеличении его содержани в 2,0-4,25 раэа в сравнений с исходным уровнем провод т медикаментозное лечение, а при отсутствии увеличени провод т хирургическое лечение ..METHOD: TREATMENT OF TYREOTHOXICOSIS PATIENTS by drug treatment with anti-thyroid agents, characterized in that, in order to reduce complications, cortisol content in the blood is determined before and after the administration of ACTH and with an increase in its content of 2.0-4.25% in comparison with drug treatment is performed at baseline, and if there is no increase, surgical treatment is performed ..
Description
медицины, в частности к эндокринологии , и может быть использовано дл вы влени показаний к консервативному или оперативному лечению больных тиреотоксикозом.medicine, in particular to endocrinology, and can be used to identify indications for conservative or surgical treatment of patients with thyrotoxicosis.
Целью изобретени вл етс - снижение осложнений.The aim of the invention is to reduce the complications.
Способ осуществл етс следующим образом.The method is carried out as follows.
У больных тиреотоксикозом в крови определ ют содержание кортизола до и после введени АКТГ, и при увеличении его содержани в 2,0-4,25 раза в сравнении с исходным уровнем провод т медикаментозное лечение, а при отсутствии увеличени - хирургическое лечение.In patients with thyrotoxicosis, the content of cortisol in the blood is determined before and after administration of ACTH, and with an increase in its content of 2.0-4.25 times compared with the initial level, medical treatment is carried out, and in the absence of an increase, surgical treatment.
П р и м е р 1. Больна Л., 19 лет, диагноз: диффузньй токсический зоб lll-IV ст., средней т жести. Болеет около 3 мес. Получала регул рно тиреостатические препараты. Однако проводима Терапи бьша малоэффективной.PRI me R 1. Sick L., 19 years old, diagnosis: diffuse toxic goiter, lll-IV degree, moderate. Sick about 3 months. Received regularly thyreostatic drugs. However, the therapy has been ineffective.
ки тиреотоксикоза были отчетливо выражены . Содержание кортизола в плазме крови 96 нг/мл. Через 60 мин, после внутримышечного введени 0,25 мг АКТЕ уровень кортизола составил 122 нг/мл (т.е. увеличение менее чем в 2 раза). Больна была подвергнута оперативному лечению.Thyrotoxicosis was clearly expressed. The plasma cortisol content is 96 ng / ml. 60 minutes after the intramuscular administration of 0.25 mg of ACTE, the level of cortisol was 122 ng / ml (i.e. an increase of less than 2 times). The patient was subjected to surgical treatment.
Пр и м е р 2. Больна В., 25 лет, диагноз: тиреотоксикоз средней т жести , диффузный зоб III ст. Продолжительность заболевани 3 мес. Исходный уровень кортизола в сыворотке 80 нг/мл, через 60 мин после внутримьшечного ,.введени 0,25 мг АКТГ содержание кортизола увеличилось до 340 нг/мл .(т.е., в 4,25 раза). Больной был назначен мерказолил, резерпин и седативные препараты. Достигнуто зутиреоидное состо ние, которое сохран етс при минимальной поддерживающей дозе в течение 1 года.Primer 2. Ill. V., 25 years old, diagnosis: moderate thyrotoxicosis, diffuse goiter, stage III. Disease duration 3 months. The initial serum cortisol level was 80 ng / ml, 60 minutes after intramuscular administration, the administration of 0.25 mg of ACTH increased the cortisol content to 340 ng / ml (i.e., 4.25 times). The patient was prescribed Mercazolil, Reserpine and sedatives. A thyroid state has been reached, which is maintained at the minimum maintenance dose for 1 year.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU813282263A SU1163862A1 (en) | 1981-04-21 | 1981-04-21 | Method of testing thyrotoxicosis cases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU813282263A SU1163862A1 (en) | 1981-04-21 | 1981-04-21 | Method of testing thyrotoxicosis cases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1163862A1 true SU1163862A1 (en) | 1985-06-30 |
Family
ID=20955751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU813282263A SU1163862A1 (en) | 1981-04-21 | 1981-04-21 | Method of testing thyrotoxicosis cases |
Country Status (1)
| Country | Link |
|---|---|
| SU (1) | SU1163862A1 (en) |
-
1981
- 1981-04-21 SU SU813282263A patent/SU1163862A1/en active
Non-Patent Citations (1)
| Title |
|---|
| Хирургическое лечение заболева-; НИИ щитовидной железы. Методические рекомендации. Харьков, 1978. * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stief et al. | Erectile responses to intracavernous papaverine and phentolamine: comparison of single and combined delivery | |
| North et al. | Effect of activated charcoal administration on acetylcysteine serum levels in humans | |
| SU1163862A1 (en) | Method of testing thyrotoxicosis cases | |
| Robinson | Aspirin and the adrenal cortex | |
| Prouse et al. | Macrocytic anaemia in patients treated with sulphasalazine for rheumatoid arthritis. | |
| Xue et al. | Therapeutic effects of electroacupuncture at ST36 acupoint on sodium-taurocholate-induced severe acute pancreatitis | |
| Murlin et al. | Some favorable effects from the alimentary administration of insulin | |
| Christensen et al. | Plasma growth hormone in acromegalic patients | |
| Jacobson et al. | Nonequality of brand name thyroxine preparations | |
| Schwartz et al. | Linear localized coumarin necrosis | |
| RU2068692C1 (en) | Method of alcoholism treatment | |
| RU2169593C2 (en) | Method for preventing and treating vascular complications of diabetes mellitus | |
| RU2139099C1 (en) | Method of treatment of angioneurotic edema | |
| RU2078575C1 (en) | Substance for gastroenteric tract ulcer and erosion treatment | |
| Marchenkova et al. | AB0627 THE EFFECT OF BIOLOGICALLY ACTIVE FOOD SUPPLEMENT WITH CALCIUM AND VITAMIN D3 ADMINISTRATION ON CALCIUM HOMEOSTASIS AND FALLS INCIDENCE IN PATIENTS WITH HIGH FRACTURE RISK UNDERGOING MEDICAL REHABILITATION | |
| SU1657190A1 (en) | A method for preventing autoimmune orchitis after cryptoorchidism surgery | |
| SU774556A1 (en) | Method of treating oral cavity mucous membrane parasthesia | |
| RU1776408C (en) | Method for treatment of glomerulonephritis cases | |
| RU2089218C1 (en) | Method of treatment of nonspecific ulcer colitis | |
| SU1194418A1 (en) | Method of treatment of children having purulent destructive pneumonia | |
| Eysselein et al. | Gastrin response to a meal before and after cutting the extrinsic nerves of the stomach in the dog. | |
| SU1156682A1 (en) | Method of treatment of chalazion | |
| UA47340A (en) | METHOD OF TREATMENT OF OBLITERATIVE DISEASES OF LOWER LIMBS ARTERIES IN PATIENTS WITH DIABETES MELLITUS | |
| McCann | Parathyroid therapy | |
| RU1802340C (en) | Method of determination of individual sensitivity to dophamine stimulators at endogenous depression treatment |